Literature DB >> 1529522

PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains.

G Fontenot1, K Johnston, J C Cohen, W R Gallaher, J Robinson, R B Luftig.   

Abstract

HIV-1 replication requires limited proteolysis of gag and gag-pol encoded precursor proteins by a specific viral proteinase (PR). Sequences of 20 different HIV-1 strains were compared in order to determine regions of conservation and variability within the PR gene. Viral strains included: (a) five new ones derived from New Orleans patient isolates, (b) four established ones grown in our laboratory, (c) eight, whose sequences were published in the Los Alamos Data Base (1990), (d) one Ugandan, and (e) two Brazilian isolates. In the first two groups, HIV proviral DNA extracted from infected lymphocytes was grown in tissue culture and directly amplified by PCR using specific primers flanking the PR gene. Amplified DNA was directly sequenced using a modified di-deoxy sequencing procedure. Sequence data showed a 25% variation among the 20 different HIV strains studied at the amino acid level, including 8% nonconservative changes and 17% conservative changes. Moreover, five noncontiguous regions were able to be delineated in which the PR showed no amino acid changes. These areas included amino acids (I) 1-9 (amino terminal sequence); (II) 21-32 (sequence around the active site); (III) 47-56 (top of the flap); (IV) 78-88; and (V) 94-99 (carboxy terminal sequence). Our results are consistent with those obtained from X-ray crystallography studies as well as single site mutational analysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1529522     DOI: 10.1016/0042-6822(92)91186-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Authors:  D D Ho; T Toyoshima; H Mo; D J Kempf; D Norbeck; C M Chen; N E Wideburg; S K Burt; J W Erickson; M K Singh
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

3.  Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.

Authors:  M B Vasudevachari; Y M Zhang; H Imamichi; T Imamichi; J Falloon; N P Salzman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.

Authors:  J Luban; C Lee; S P Goff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.

Authors:  A K Patick; H Mo; M Markowitz; K Appelt; B Wu; L Musick; V Kalish; S Kaldor; S Reich; D Ho; S Webber
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.

Authors:  M J Otto; S Garber; D L Winslow; C D Reid; P Aldrich; P K Jadhav; C E Patterson; C N Hodge; Y S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

Authors:  A K Patick; R Rose; J Greytok; C M Bechtold; M A Hermsmeier; P T Chen; J C Barrish; R Zahler; R J Colonno; P F Lin
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.